Eight Mechanisms.
One Protocol.
Everything Changes.
Crush Inflammation
KPV, PEA, GHK-Cu, and BPC-157 all suppress NF-κB from different angles simultaneously. Four compounds, four mechanisms, one inflammatory pathway shut down from every direction.
Heal Faster
TB-500 drives angiogenesis and cell migration. BPC-157 repairs tendons, gut lining, and epithelial barriers. GHK-Cu increases collagen 9× in tissue models. Joints, tendons, gut, skin — everything repairs faster.
Activate Your Immune System
Thymosin Alpha-1 is an approved immune drug in 35+ countries with 4,400+ patients across 80+ clinical trials. T-cells, NK cells, dendritic cell maturation. Not "immune support" — immune activation.
Reverse Aging — Proven
Epithalon produced 33% average telomere elongation in human lymphocytes. Confirmed in 2025 across multiple cell lines via both telomerase and ALT pathways. 4× survival increase in animal models. This isn't theory — it's measured.
Restore Your Sleep
Epithalon restored melatonin synthesis 1.6× in elderly subjects. Not a sleep supplement — it repairs the pineal gland's output. Deep, restorative sleep returns because the signal returns.
Better Skin & Hair
GHK-Cu modulates 31% of human genes and your natural levels drop 60% by age 60. Collagen synthesis, elastin production, wound closure, follicle support. Visible changes people actually notice.
Fix Your Gut
BPC-157 repairs the epithelial barrier from both sides — injectable and oral. KPV suppresses mucosal inflammation via PepT1 (upregulated in inflamed tissue). NAC breaks down biofilm shields. Three mechanisms, one gut.
Detox at the Cellular Level
NAC is the rate-limiting precursor for glutathione — your master antioxidant. GHK-Cu upregulates the ubiquitin proteasome system by 1,056%, accelerating cellular cleanup of damaged and misfolded proteins.
The Stack
KLOW
Should
Have Been.
Six injectable peptides. Oral capsule companion. A 6-month alternating active/maintenance protocol that cycles immune activation and longevity signaling while keeping gut-immune support continuous.
See the FormulaWhat's wrong with standard KLOW?
KLOW is a convenience formulation — four compounds at a fixed 5:1:1:1 ratio regardless of pharmacokinetics, mechanism, or optimal delivery route. SuperKLOW fixes every one of those problems.
No immune activation layer
KLOW repairs damaged tissue but doesn't activate the immune response that clears the underlying infection. Thymosin Alpha-1 fills this gap — an approved drug in 35+ countries with 80+ clinical trials and 4,400+ patients. The mechanism KLOW never had.
TB-500 was chronically underdosed
Standard KLOW delivers 0.32mg TB-500 per dose — below any meaningful threshold. SuperKLOW delivers 0.5mg daily. With a 2-3 day half-life, daily dosing accumulates to steady state in 10-15 days regardless — no aggressive loading needed for a continuous maintenance protocol.
KPV needs both routes
KPV works via PepT1 mucosal transporter in the gut lining for local gut-immune effects, but also has systemic anti-inflammatory action via SubQ. SuperKLOW uses both — SubQ in active months for systemic effects, oral every month for continuous gut-local PepT1-mediated support.
No longevity signal
Epithalon activates telomerase — Khavinson's studies showed 33% average telomere elongation in human lymphocytes, confirmed by a 2025 Biogerontology study across multiple cell lines. It also restored melatonin synthesis 1.6× in elderly subjects. Standard KLOW has no longevity component. SuperKLOW adds 300mcg/day at the research-accurate dose, auto-cycled via the two-vial system.
The Two-Vial Active Month
Each active month (1, 3, 5) ships as two vials — M1a and M1b. Use M1a first (days 1–15), then M1b (days 16–30). Epitalon cycling happens automatically.
The Daily Capsule.
Four Compounds.
Two Caps.
Two capsules daily on empty stomach alongside the injectable. KPV, BPC-157, PEA, and NAC — continuous gut-immune support that never cycles off, even during maintenance months.
BPC-157 1mg · Oral epithelial barrier repair — complements injectable route
PEA 600mg · Ultra-micronized PPAR-α anti-inflammatory, mast cell stabilization
NAC 800mg · Biofilm matrix disruptor, glutathione precursor
2 capsules daily · Empty stomach · Continuous all 6 months
KPV + BPC-157
KPV suppresses NF-κB via PepT1 mucosal uptake — the transporter is upregulated in inflamed colon tissue, meaning the target imports more peptide during disease states (Dalmasso et al., Gastroenterology). BPC-157 oral complements the injectable route — originally isolated from gastric juice, stable in stomach acid, with human trial data showing 80–100% resolution in interstitial cystitis.
PEA (Ultra-Micronized)
600mg ultra-micronized palmitoylethanolamide. PPAR-α activation inhibits NF-κB, stabilizes mast cells, and enhances endocannabinoid signaling. Backed by a 636-patient RCT showing large effect size (Cohen's d = 1.35) at 600mg. Ultra-micronized form ensures bioavailability — standard PEA particles are too large for efficient absorption.
NAC
800mg N-Acetylcysteine directly breaks down the extracellular polysaccharide matrix that forms the biofilm shield. Systematic review (Dinicola et al.) confirmed biofilm disruption across MRSA, Pseudomonas, and S. epidermidis. Increases antibiotic penetration into deep biofilm layers. Also the rate-limiting precursor for glutathione synthesis.
6-Month Alternating Protocol.
Active months ship as two vials with Epitalon cycling built in. Maintenance months are a single vial. Oral capsule runs continuously — never cycles off.
Where to Inject:
Systemic vs. Local
The injection site matters — especially for peptides with short plasma half-lives. Here's how to optimize delivery based on your goal.
Systemic Effects
For: Skin, hair, connective tissue regeneration, general anti-aging
Standard abdominal subcutaneous injection works perfectly. GHK-Cu, BPC-157, and TB-500 Fragment circulate systemically to reach skin, follicles, and connective tissues throughout the body. You want broad distribution — abdominal SC provides exactly that.
Local Injury Targeting
For: Specific injury sites needing accelerated repair
Inject subcutaneously over or near the affected area — within 1-2 inches of the injury site. Despite short plasma half-life, these peptides concentrate at injury sites where fibrin and exposed extracellular matrix bind them. Local injection delivers higher concentrations directly to target tissue before systemic clearance.
Why Short Half-Life Doesn't Mean Ineffective
TB-500 Fragment and BPC-157 have plasma half-lives measured in hours, not days. That sounds like a problem — until you understand how regenerative peptides actually work:
- Tissue uptake decouples from plasma clearance. What gets measured in pharmacokinetic studies is circulating plasma concentration. These peptides rapidly partition into tissues, bind their targets (G-actin, intracellular pools), and accumulate at injury sites. Once in tissue, plasma assays can't see them — but the biology is still happening.
- The signal is catalytic, not stoichiometric. TB-500 doesn't need to occupy actin continuously. A brief pulse triggers downstream events — lamellipodia formation, cell migration, gene expression shifts (KLF2, VEGF). The migration machinery keeps running on its own momentum for hours to days after. You're flipping a switch, not holding it down.
- Injury-site concentration is what matters. TB4 and BPC-157 are preferentially retained at sites of tissue damage. Fibrin binds them, exposed actin from lysed cells binds them, the inflammatory milieu concentrates them. Even as plasma levels crash, the therapeutically relevant concentration at the wound bed is much higher and lasts much longer.
- Clinical dosing confirms this. Wound healing and tissue repair studies use twice-weekly or even weekly dosing despite short plasma half-life — because the mechanism doesn't require sustained plasma exposure. It requires getting the molecule to the target tissue, where it triggers cascades that outlast the peptide itself.
Consult qualified medical professionals before use. Not FDA approved. Not for human therapeutic use.